Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan;365(1):93-98.
doi: 10.1016/j.amjms.2022.07.007. Epub 2022 Aug 12.

Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab

Affiliations
Review

Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab

Georgios Tsioulos et al. Am J Med Sci. 2023 Jan.

Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a multisystem antineutrophil cytoplasmic antibody (ANCA) positive vasculitis, characterized by the presence of chronic rhinosinusitis, asthma and prominent peripheral blood eosinophilia. Although the most commonly involved organ is the lung, followed by the skin, EGPA can affect any organ system. Herein, we present the complicated case of an 18-year-old male patient with severe life-threatening EGPA, with central nervous system, cardiac and gasterointestinal involvement, which was resistant to initial treatment with glucocorticoids and cyclophosphamide. The patient responded well, achieving complete remission after the addition of rituximab and mepolizumab to glucocorticoids and cyclophosphamide.

Keywords: Cyclophosphamide; Eosinophilic granulomatosis with polyangiitis; Glucocorticoids; Mepolizumab; Rituximab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest There are no conflict sof interest regarding this manuscript.

Similar articles

Cited by

MeSH terms